Clinical Trials Browser

Phase 1/2 × NIH × talazoparib × Clear all

NCT02116777 2021-03-26

Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies

Phase 1/2 Completed

40 enrolled 32 charts

Central Nervous System Neoplasms, Neuroectodermal Tumors, Primitive, Peripheral

NCT01989546 2021-02-23

Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations

Phase 1/2 Completed

9 enrolled 11 charts

BreastGynecologicOther solid neoplasm

Advanced Ovarian Cancer